Drug Profile
Bendamustine - Astellas Pharma GmbH
Alternative Names: BENDA; Bendam; Bendamus; Bendamustine HCl; Bendamustine hydrochloride; Bentaman; Cytostasan; Endexin; Esevaril; Innomustine; Levact; Ribomustin; Ribomustine; Ribovact; SDX-105; SyB C-0501; SyB L 1701; SyB L 1702; SyB L-0501; SyB L-0501RI; SyB L-1701 [RTD]; SyB L-1702 [RI]; Symbenda; Treakisym; TreandaLatest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Jenapharm
- Developer Astellas Pharma GmbH; Cantonal Hospital of St Gallen; Eisai Co Ltd; Emory University; Foundation GIMEMA; Genentech; GlaxoSmithKline KK; INNOPHARMAX; Istituto Clinico Humanitas; Janssen-Cilag; Keio University; Memorial Sloan-Kettering Cancer Center; Mundipharma International; Northside Hospital; PETHEMA Foundation; St. Jude Childrens Research Hospital; SymBio Pharmaceuticals; Teva Pharmaceutical Industries; University of Gottingen; University of Texas M. D. Anderson Cancer Center
- Class Antineoplastics; Benzimidazoles; Butyric acids; Nitrogen mustard compounds; Nitrosourea compounds; Small molecules
- Mechanism of Action Alkylating agents; Antimetabolites; DNA cross linking agents
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Breast cancer; Cancer; Chronic lymphocytic leukaemia; Hodgkin's disease; Mantle-cell lymphoma; Multiple myeloma; Non-Hodgkin's lymphoma
- Registered Diffuse large B cell lymphoma
- Phase II Amyloid light-chain amyloidosis; B-cell lymphoma; HER2 negative breast cancer; Marginal zone B-cell lymphoma
- Phase I/II Follicular lymphoma
- No development reported Acute myeloid leukaemia; Precursor cell lymphoblastic leukaemia-lymphoma; Solid tumours; Systemic lupus erythematosus
- Discontinued Chronic myeloid leukaemia; Chronic myelomonocytic leukaemia; Myelodysplastic syndromes
Most Recent Events
- 10 Dec 2022 Efficacy and safety data from a phase II trial in Mantle-cell lymphoma presented at the 64th American Society of Hematology Annual Meeting and Exposition (ASH-2022)
- 10 Dec 2022 MundiPharma terminates a phase-I/II clinical trials in Follicular lymphoma (Combination therapy) in United Kingdom, Germany, Netherlands (IV) due to slow enrollment prior to December 2022 (EudraCT2011-000097-56) (NTR3028)
- 28 Jun 2022 No recent reports of development identified for preclinical development in Systemic-lupus-erythematosus in Japan (PO)